{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.00"},{"groupId":"OG001","spread":"0.00","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"title":"Cycle 1 Day 1- pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1920","value":"3360"},{"groupId":"OG001","spread":"1780","value":"3060"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Cycle 1 Day 1- 2 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"781","value":"727"},{"groupId":"OG001","spread":"806","value":"663"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"Cycle 1 Day 15 - pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2100","value":"4100"},{"groupId":"OG001","spread":"2000","value":"4340"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"title":"Cycle 1 Day 15- 2 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1000","value":"687"},{"groupId":"OG001","spread":"745","value":"672"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 3 Day 1 - pre-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"PK concentrations of capmatinib. Plasma concentrations of capmatinib were measured using validated liquid chromatography-tandem mass spectrometry (LCMS/MS) methods with a lower limit of quantification (LLOQ) of approximately 1.0 ng/mL.\n\nCapmatinib concentration data was summarized for Cohorts 1a, 1b, 2, 3, 4, 5a and 5b when capmatinib was administered in fasted state; and for Cohorts 6 and 7 when capmatinib was administered with or without food.","dispersionType":"Standard Deviation","groups":[{"description":"Participants from Cohorts 1a, 1b, 2, 3, 4, 5a and 5b who received capmatinib in fasted state","id":"OG000","title":"Cohorts 1-5: Capmatinib Administration in Fasted State"},{"description":"Participants from Cohorts 6 and 7 who received capmatinib with or without food","id":"OG001","title":"Cohorts 6-7: Capmatinib Administration With ot Without Food"}],"paramType":"MEAN","populationDescription":"Participants who received at least one dose of capmatinib and provided at least one evaluable pharmacokinetic concentration for capmatinib at the specified time points. Participants who received capmatinib under the same administration conditions (fasted state or with/without food) were pooled together.","reportingStatus":"POSTED","timeFrame":"Cycle (C) 1 Day (D) 1 predose and 2 hours post-dose, C1D15 pre-dose and 2 hours post-dose, C3D1 pre-dose. Each Cycle is 21 days","title":"Pharmacokinetic (PK) Concentrations of Capmatinib","type":"SECONDARY","unitOfMeasure":"nanogram/mililiter (ng/ml)"}